p63 Antibody / Tumor protein 63

Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT

Optimal dilution of the recombinant p63 antibody should be determined by the researcher.

p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide

Full-length human recombinant protein was used as the immunogen for the recombinant p63 antibody.

This recombinant p63 antibody is available for research use only.

Nuclear

Protein A affinity chromatography

Human, Mouse, Rat

Q9H3D4